Investigation of Prostate Cancer Risk Factors and Targeted Screening
Aim 1: To compare the risk estimates of factors associated with prostate cancer incidence and mortality between the two trial arms. Aim 2: Compare the incidence rates of prostate cancer, aggressive prostate cancer and prostate cancer specific mortality between the two arms for each cohort of men. 1. men with 0 co-morbidities (reported on BQX) 2. men with 1 co-morbidity (reported on the BQX) 3. men with >=2 co-morbidities (reported on the BQX) 4. men with no family history of prostate cancer (reported on BQX) 5. men with one affected first degree relative (reported on BQX) 6. men with more than one affected relative (reported on BQX) 7. men with no family history of any cancer (reported on BQX) 8. men with any family history of any cancer (reported on BQX).
Anthony D’Amico (Harvard)
Gerry Andriole (Wash U)
Phil Castle (DCEG, NCI)
Paul Doria-Rose (DCP, NCI)
Robert Grubb (Wash U)
Grant Izmirlian (DCP, NCI)
Lawrence Ragard (Westat)
Ming Chen (UConn)
Paul Pinsky (DCP, NCI)
-
Comorbidity and mortality results from a randomized prostate cancer screening trial.
Crawford ED, Grubb R, Black A, Andriole GL, Chen MH, Izmirlian G, Berg CD, D'Amico AV
J. Clin. Oncol. 2011 Feb; Volume 29 (Issue 4): Pages 355-61 PUBMED